Lightspeed India Partners

Lightspeed India Partners is the Bengaluru-based arm of the Lightspeed global franchise, established when Bejul Somaia joined in 2008 to lead India and now operating as a multi-stage, multi-fund practice with deep cross-pollination back to the Menlo Park parent. The most recent India-dedicated vehicle, Lightspeed India Partners III, closed at $275M in 2020, while the broader global Lightspeed platform deploys multi-billion-dollar funds whose growth-stage capacity is fully available to Indian portfolio companies as they scale through Series C and beyond. The current India partner group includes Bejul Somaia, Dev Khare, Hemant Mohapatra, Akshay Bhushan, Vaibhav Agrawal, and Harsha Kumar; Khare in particular has publicly framed Lightspeed’s bet as roughly one-third weighted toward AI-native companies in the current vintage, a higher concentration than most generalist Indian funds are willing to commit to publicly. For healthcare founders, the relevant signal is that Lightspeed has graduated from being a generalist consumer and SaaS investor in India to running a distinct healthcare and healthcare-AI thesis, and Qure.ai is the proof. In 2024 Lightspeed led Qure’s $65M Series D, taking pole position on what is arguably the most globally relevant Indian clinical AI company, with funds earmarked for international expansion and continued investment in generative AI models for disease detection. The Qure round signaled that Lightspeed is comfortable underwriting Indian-origin clinical AI franchises at growth-stage valuations on the strength of US and European reimbursement pipelines, not just emerging-market hospital deployments. Earlier in the cycle, Lightspeed India backed Innovaccer when it was an India-origin company before its US migration; the firm exited that position with a reported 30 percent IRR after Kaiser Permanente entered the cap table, a return that has materially shaped how the partnership thinks about US-bound healthcare AI franchises with Indian engineering DNA. Beyond Qure and Innovaccer, the firm has named Triomics (AI for clinical trials), Emversity (healthcare workforce upskilling), HealthPlix (doctor-facing EMR and prescription software), and Acko (digital-first health insurance distribution) among its healthcare and adjacent-insurance bets, covering AI for clinical trials, healthcare workforce upskilling, doctor-facing EMR and prescription software, and digital-first health insurance distribution respectively. The Lightspeed thesis underneath these bets is that India’s combination of data scale, clinician volume, and frontier engineering talent makes it one of the few geographies where application-layer healthcare AI can be built with genuine technical defensibility while maintaining a US-export optionality, a thesis the firm has articulated publicly through its healthcare AI essays on the Lightspeed blog. Stage coverage runs from Seed through Series F via the global platform, with the India seed and Series A sweet spot in the $1M to $5M band and growth checks scaling well into the tens of millions out of the parent funds; the global continuity matters because India healthcare AI companies frequently raise their growth rounds from US Lightspeed partners as US payer and provider revenue eclipses Indian revenue. Lightspeed leads or co-leads most of its early-stage deals and runs a hands-on board engagement model. Founders who fit are technical India-origin teams building clinical AI with US-export potential, generative AI applied to clinical trials and revenue cycle, doctor-facing software with a defensible workflow moat, digital-first health insurance and payer infrastructure, and healthcare workforce platforms that solve a structural India clinician supply problem. Founders who do not fit include therapeutics and biotech, hardware-only medtech without a meaningful software wedge, consumer wellness brands without a technology moat, and Indian-only plays without a credible international expansion thesis where the unit economics demand global revenue to justify growth-stage valuations. The intro path is canonical Lightspeed: portfolio-CEO referral from the Qure, HealthPlix, or Acko anchor, the Lightspeed Scout network which has notable Indian operator depth, or direct partner outreach with a substantive technical brief that demonstrates engineering depth rather than narrative polish. In the pitch, lead with the technical wedge and the data moat, demonstrate how India scale informs your model in ways US-only companies cannot replicate, articulate the regulatory path on whichever side of the Pacific you intend to monetize (FDA, CE, CDSCO depending on the wedge), and bring concrete evidence of clinical or workflow efficacy rather than relying on TAM rhetoric. The caveats: the firm is in active healthcare-AI deal flow and competitive intensity around Lightspeed’s preferred archetypes is high, partner attention compounds toward a small number of conviction bets per fund, the global platform’s growth-stage discipline means Series A-stage portfolio companies are continuously benchmarked against their global Lightspeed peers in the US and Israel, and the firm’s preference for technical founder-CEOs can be a friction point for commercially-led teams.